ACTRN12606000330549Not yet recruitingPhase 2
An Open Label, Multi Centre, Phase II Study to Evaluate the Safety and Efficacy of Coramsine Injection in Patients with Melanoma
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Solbec Pharmaceuticals Ltd
- Enrollment
- 56
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Non-randomised trial
- Primary Purpose
- Treatment
- Masking
- Open (masking not used)
Eligibility Criteria
- Ages
- 18 Years to ot stated (—)
- Sex
- All
Inclusion Criteria
- •1. Histologically confirmed diagnosis of stage IV or unresectable stage III Melanoma 2. Patients with bi-dimensionally measurable disease according to RECIST criteria 3. Patients who are able and willing to provide written informed consent to participate in the study. 4. Patients must have adequate haematological, hepatic and renal function 5. ECOG Performance status of 0-2. 6. Life expectancy of at least 16 weeks. 7. Fertile males and females must agree to the use of an adequate form of contraception. Negative pregnancy test is required in female patients of child-bearing potential.
Exclusion Criteria
- •1. Patients with an active infection requiring oral or intravenous antibiotics 2. Patients with significant cardiac or pulmonary disease or evidence of any other significant medical condition, which in the opinion of the principal investigator could impair the ability of the patient to participate in the trial. 3. Patients with recent (< 6 months) peptic ulcerations or upper GI bleeding. 4. Pregnant or lactating women. 5. Reactions to the Solanum species (potatoes, tomatoes, aubergines and capsicum). 6. History of adverse reactions to related compounds. 7. Active brain or other CNS metastases. Stable/controlled brain metastases are permitted following treatment with surgery or radiation therapy. A minimum of 4 weeks must have elapsed since surgical or radiation treatment of brain metastases. 8. Unwilling/unable to have a venous access device inserted. 9. Known seropositive to HIV, Hepatitis B or Hepatitis C 10. Any other active malignancy 11. Patients must not have had any radiotherapy for 3 weeks prior to entering the study, and must be fully recovered from the acute effects of any prior radiotherapy. 12. Patients must not have greater than 2 previous regimens of chemotherapy treatment for Melanoma. Prior treatment with cytokines, vaccines, antiangiogenic agents or signal transduction inhibitors is permitted. 13. Patients must not have had any other tumour treatment medications for 30 days prior to entering the study. 14. Patients must not be actively receiving any other investigational therapy, nor received any experimental agents within the previous 30 days. 15. Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.
Investigators
Similar Trials
Not yet recruiting
Phase 2
An Open Label, Multi Centre, Phase II Study to Evaluate the Safety and Efficacy of Coramsine Injection in Patients with Renal Cell CarcinomaAdvanced Renal Cell CarcinomaCancer - Renal Cell CarcinomaACTRN12606000099527Solbec Pharmaceuticals Ltd56
Completed
Phase 1
A clinical trial to study the safety and efficacy of a new compound P276-00 in the treatment of multiple myelomaCTRI/2008/091/000004Piramal Life Science26
Active, not recruiting
Not Applicable
An open label, multicenter Phase 1-2 study to investigate the effectiveness, safety and immunogenicity of a monotherapy with intradermal IMA910 plus GM-CSF following pre-treatment with low-dose cyclophosphamide in advanced colorectal carcinoma patients who have successfully completed a 12 week first line treatment with oxaliplatin-based chemotherapyAdult HLA-A*02-positive patients who have been diagnosed with unresectable, locally advanced and/or metastatic colorectal cancer before first-line chemotherapy. Patients must have completed a 12 week first-line oxaliplatin-based standard chemotherapy (e.g. FOLFOX or XELOX) with either complete or partial response or stable disease as the outcome.EUCTR2007-005666-12-DEimmatics biotechnologies GmbH90
Active, not recruiting
Not Applicable
An open label, multicenter Phase 1-2 study to investigate the effectiveness, safety and immunogenicity of a monotherapy with intradermal IMA910 plus GM-CSF following pre-treatment with low-dose cyclophosphamide in advanced colorectal carcinoma patients who have successfully completed a 12 week first line treatment with oxaliplatin-based chemotherapyEUCTR2007-005666-12-LVimmatics biotechnologies GmbH9
Active, not recruiting
Not Applicable
An open label, multicenter Phase 1-2 study to investigate the effectiveness, safety and immunogenicity of a monotherapy with intradermal IMA910 plus GM-CSF following pre-treatment with low-dose cyclophosphamide in advanced colorectal carcinoma patients who have successfully completed a 12 week first line treatment with oxaliplatin-based chemotherapyEUCTR2007-005666-12-BGimmatics biotechnologies GmbH90